Monitor regulatory filings (HSR, SEC S-4) and BioLife shareholder vote for deal closure timeline. Repligen's full Q2 earnings on July 28 will provide further detail on organic growth trajectory and margin expansion. The acquisition positions Repligen in the high-growth cell therapy market, but integration risk and potential dilution from share issuance are key watchpoints.
Price Chart
Executive Summary
Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal, expanding its cell therapy capabilities. The company also reported preliminary Q2 2026 revenue growth of ~12% (13% organic) and expects strong margin expansion. The transaction is expected to close in Q4 2026 and be accretive to adjusted EPS by at least $0.05 in year one.
Key Financial Metrics
Key Facts
- Acquisition of BioLife Solutions for $11.25 cash + 0.1442 RGEN shares per BLFS share, total enterprise value ~$1.5B
- Implied premium of 24% to 90-day VWAP
- Expected to close in Q4 2026, subject to regulatory and BioLife shareholder approvals
- Repligen expects at least $20M synergies in year one, $30M in year two
- Accretive to adjusted EPS by at least $0.05 in year one and $0.25 in year two
- Preliminary Q2 2026 revenue growth of ~12% reported, 13% organic vs Q2 2025
- BioLife preliminary Q2 2026 revenue of $28.5M, up 21% YoY
- Repligen expects strong year-over-year margin expansion in Q2 2026
Financial Impact
~$1.5B enterprise value acquisition; Repligen Q2 revenue growth ~12% reported; BioLife Q2 revenue $28.5M
Risk Factors
- Integration risk and potential disruption to existing operations
- Failure to obtain regulatory or shareholder approvals
- Dilution from issuance of ~7.2M RGEN shares (approx 12.8% of outstanding)
- Synergy targets may not be achieved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (RGEN) — Batch item 1 | 0001193125-26-311411 |
| Document: 0001193125-26-311411-index-headers.html | 0001193125-26-311402 |
| Document: 0001193125-26-311411-index.html | 0001193125-26-311411 |
| Document: 0001193125-26-311411.txt | 0001193125-26-311411 |
| 8-K Filing (RGEN) — Batch item 5 | 0001193125-26-311402 |
| 8-K Data (Synthetic) | 0001193125-26-311411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | S-4 | $181.69 $184.53 | ▲ +1.56% | ▲ +0.59% | $182.92 (+0.68%) |
Jul 28, 2026 9w ago | 8-K | $145.34 $181.69 | ▲ +25.01% | ▲ +21.63% | $182.92 (+25.86%) |
Jul 22, 2026 10w ago | 425 / 8-K | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $182.92 (+30.57%) |
Jul 22, 2026 10w ago | Press Release | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $182.92 (+30.57%) |
Jun 11, 2026 16w ago | Institutional Cluster | $130.59 $144.24 | ▲ +10.45% | ▲ +8.67% | $182.92 (+40.07%) |
May 5, 2026 21w ago | 8-K | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $182.92 (+45.63%) |
May 5, 2026 21w ago | Press Release | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $182.92 (+45.63%) |
Apr 22, 2026 23w ago | Press Release | $124.40 $108.52 | ▼ −12.77% | ▼ −15.93% | $182.92 (+47.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access